New vaccine against acne
Regardless of age, many acne patients experience enormous suffering and are unable to use many existing methods of treatment such as creams, antibiotics and vitamin A preparations on a permanent basis.
Three reasons are crucial for the formation of acne: increased sebum production, genetic factors and bacteria. Research by the biotech company Origimm applies to the latter. Under the “test tube-leadership” of molecular biologist Dr. Sanja Selak intensive research is being carried out on a vaccine against acne. “Our goal is to develop a vaccine that activates the body’s immune system and stimulates the formation of protective immune factors and antibodies against the acne bacteria,” said Selak.
In preparation for a large clinical trial, which protein combination produces the most effective acne bacteria antibodies is currently being investigated in the Origimm laboratory. Selak has also developed “ProVaDis” a new, innovative method whereby those proteins which have the highest immunization can be effectively identified. If the optimal inoculum composition is found, the vaccine will be tested in a clinical study. The benefits of vaccination: it is inexpensive, it does not cause side effects, and it avoids the formation of large acne lesions deep in the skin. Origimm was funded by the Vienna Business Agency in the course of the call “FemPower 2012”. “Because of the funding I was able to hire Christine Triska a highly experienced laboratory technician. Extremely important for the success of the project.”
Services/grants provided by the Vienna Business Agency:
- Grants received through the Research programme
- Support via Technology Consulting and LISAvienna
Origimm Biotechnology GmbH
Picture: Dr. Sanja Selak, Christine Triska (c) Wirtschaftsagentur